Application progress of tuberculosis interferon-γ release assay in immune checkpoint inhibitors treatment
10.12025/j.issn.1008-6358.2025.20250327
- VernacularTitle:结核特异性干扰素γ释放试验在免疫检查点抑制剂治疗中的应用进展
- Author:
Minghui WANG
1
;
Hongni JIANG
2
Author Information
1. Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
2. Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China;Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital (Xiamen Branch), Fudan University, Xiamen 361015, Fujian, China.
- Publication Type:Review
- Keywords:
tuberculosis;
interferon-γ release assay;
immune checkpoint inhibitor
- From:
Chinese Journal of Clinical Medicine
2026;33(1):134-142
- CountryChina
- Language:Chinese
-
Abstract:
Immune checkpoint inhibitors (ICIs) are being widely applied in the treatment of various malignancies, significantly prolonging survival and improving quality of life. However, consequent immune-related adverse events have emerged as new clinical challenges. As a high-burden country for tuberculosis (TB), China faces particular concern regarding the impact of ICIs therapy on TB reactivation in cancer patients. Based on the detection principles of the TB interferon-γ release assay (TB-IGRA), this review explores its potential value in predicting ICIs efficacy and proposes a management algorithm for pulmonary TB patients undergoing ICIs treatment, aiming to maximize clinical benefits while ensuring safety.
